Inhalon Biopharma
Inhalon Biopharma is a clinical-stage biotechnology company focused on developing inhaled antibody treatments for acute respiratory infections such as RSV, SARS-CoV-2, human metapneumovirus, and influenza. Their innovative inhaled drug platform aims to provide effective, self-administered treatments that can be used at home, addressing a significant unmet medical need for respiratory infections.
Industries
Nr. of Employees
small (1-50)
Inhalon Biopharma
Carrboro, North Carolina, United States, North America
Products
Inhaled monoclonal antibody candidates for acute respiratory infections
A pipeline of inhaled antibody therapeutics developed for direct delivery to the lung to treat or prevent acute respiratory infections including RSV, SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
Inhaled Antibody Treatments
Inhalon is developing inhaled antibody treatments designed to provide immediate intervention, be self-administered, and work for all age groups. The treatment involves inhaling an antibody mist generated by a handheld vibrating nebulizer from third parties, which aerosolizes the antibody drug without changing its properties.
IN-006
An inhaled antibody treatment for COVID-19 that demonstrates stable nebulization and muco-trapping properties, supporting its development as a potent, dose-saving inhaled therapy.
IN-007
An inhaled ACE2-targeting therapeutic in development for SARS-CoV-2.
Mota-MT
A muco-trapping antibody against RSV delivered via nebulized inhalation, shown to reduce viral load significantly in RSV-infected neonatal lambs and reduce inflammation and airway remodeling.
ACE2-(G4S)6-FC decoy
A muco-trapping ACE2 decoy molecule that binds and neutralizes SARS-CoV-2 variants with picomolar potency, delivered intranasally to reduce viral load in infected hamsters.
Inhaled monoclonal antibody candidates for acute respiratory infections
A pipeline of inhaled antibody therapeutics developed for direct delivery to the lung to treat or prevent acute respiratory infections including RSV, SARS-CoV-2, human metapneumovirus (hMPV), and influenza.
Inhaled Antibody Treatments
Inhalon is developing inhaled antibody treatments designed to provide immediate intervention, be self-administered, and work for all age groups. The treatment involves inhaling an antibody mist generated by a handheld vibrating nebulizer from third parties, which aerosolizes the antibody drug without changing its properties.
IN-006
An inhaled antibody treatment for COVID-19 that demonstrates stable nebulization and muco-trapping properties, supporting its development as a potent, dose-saving inhaled therapy.
IN-007
An inhaled ACE2-targeting therapeutic in development for SARS-CoV-2.
Mota-MT
A muco-trapping antibody against RSV delivered via nebulized inhalation, shown to reduce viral load significantly in RSV-infected neonatal lambs and reduce inflammation and airway remodeling.
ACE2-(G4S)6-FC decoy
A muco-trapping ACE2 decoy molecule that binds and neutralizes SARS-CoV-2 variants with picomolar potency, delivered intranasally to reduce viral load in infected hamsters.
Services
Partnership-based selection, licensing, and co-development of antibody assets for inhaled delivery, including academic in-licensing and external antibody integration.
End-to-end preclinical efficacy testing, IND-enabling activities, Phase 1/1b clinical study execution (safety, tolerability, respiratory PK), and regulatory support for inhaled antibody candidates.
Assay development and automated workflows for ELISA, mucosal functional assays, cell-based antiviral tests, and stability testing of antibodies during nebulization.
Partnership-based selection, licensing, and co-development of antibody assets for inhaled delivery, including academic in-licensing and external antibody integration.
End-to-end preclinical efficacy testing, IND-enabling activities, Phase 1/1b clinical study execution (safety, tolerability, respiratory PK), and regulatory support for inhaled antibody candidates.
Assay development and automated workflows for ELISA, mucosal functional assays, cell-based antiviral tests, and stability testing of antibodies during nebulization.
Expertise Areas
- Inhaled therapeutics for acute respiratory infections
- Monoclonal antibody engineering and glycoengineering
- Pulmonary drug delivery and aerosolization
- Preclinical animal models for respiratory viruses (large- and small-animal)
Key Technologies
- Handheld vibrating nebulizer aerosol delivery
- Muco-trapping antibody mechanism
- Inhaled monoclonal antibody formulations
- ACE2-based decoy biologics
News & Updates
Inhalon announced a partnership with Celltrion to develop an inhaled form of regdanvimab for COVID-19, with topline results expected in 2022. The therapy aims to treat COVID-19 patients at home using inhaled muco-trapping antibodies.
Inhalon announced the dosing of the first patient in a Phase 1 safety and tolerability study of IN-006, an inhaled muco-trapping formulation of regdanvimab, for COVID-19. The study is supported by USAMRDC.
Preclinical data published in Advanced Science and Bioengineering and Translational Medicine demonstrate the efficacy of inhaled antibodies against RSV and SARS-CoV-2 in animal models.
Inhalon Biopharma Announces Progress at 9th Annual Inhalation and Respiratory Drug Delivery Congress
Sam Lai, Ph.D., discussed the company's progress in inhaled treatments for respiratory infections, including recent clinical and preclinical results.
Inhalon announced a licensing agreement with the University of Georgia to develop treatments for human metapneumovirus (hMPV).
The company announced plans to present at BIO 2024, highlighting its pipeline for inhaled treatments for respiratory infections.
Inhalon announced a partnership with Celltrion to develop an inhaled form of regdanvimab for COVID-19, with topline results expected in 2022. The therapy aims to treat COVID-19 patients at home using inhaled muco-trapping antibodies.
Inhalon announced the dosing of the first patient in a Phase 1 safety and tolerability study of IN-006, an inhaled muco-trapping formulation of regdanvimab, for COVID-19. The study is supported by USAMRDC.
Preclinical data published in Advanced Science and Bioengineering and Translational Medicine demonstrate the efficacy of inhaled antibodies against RSV and SARS-CoV-2 in animal models.
Inhalon Biopharma Announces Progress at 9th Annual Inhalation and Respiratory Drug Delivery Congress
Sam Lai, Ph.D., discussed the company's progress in inhaled treatments for respiratory infections, including recent clinical and preclinical results.
Inhalon announced a licensing agreement with the University of Georgia to develop treatments for human metapneumovirus (hMPV).
The company announced plans to present at BIO 2024, highlighting its pipeline for inhaled treatments for respiratory infections.